| scholarly article | Q13442814 |
| P50 | author | Matthew Farren | Q42777706 |
| Tanios Bekaii-Saab | Q43376169 | ||
| P2093 | author name string | Gregory B Lesinski | |
| Jennifer Yang | |||
| Daniel Ahn | |||
| P2860 | cites work | Worldwide trends in mortality from biliary tract malignancies | Q21093310 |
| First-in-class, first-in-human phase I results of targeted agents: highlights of the 2008 American society of clinical oncology meeting | Q21198874 | ||
| B55β-associated PP2A complex controls PDK1-directed myc signaling and modulates rapamycin sensitivity in colorectal cancer | Q24307014 | ||
| A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling | Q24599676 | ||
| Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas | Q24610836 | ||
| The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation | Q24616946 | ||
| NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas | Q24646237 | ||
| Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells | Q24651232 | ||
| The selectivity of protein kinase inhibitors: a further update | Q24654622 | ||
| Structural Determinants of Phosphoinositide 3-Kinase Inhibition by Wortmannin, LY294002, Quercetin, Myricetin, and Staurosporine | Q27628650 | ||
| The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer | Q27651832 | ||
| Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer | Q27666699 | ||
| Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin | Q27684091 | ||
| Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers | Q27851426 | ||
| NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. | Q27851451 | ||
| MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study | Q27852083 | ||
| Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3. | Q27852991 | ||
| PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer | Q27860985 | ||
| High frequency of mutations of the PIK3CA gene in human cancers | Q28131776 | ||
| Prospects for phosphoinositide 3-kinase inhibition as a cancer treatment | Q28188301 | ||
| A synthetic inhibitor of the mitogen-activated protein kinase cascade | Q28367955 | ||
| Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling | Q28638664 | ||
| A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002) | Q28640016 | ||
| STATs in cancer inflammation and immunity: a leading role for STAT3 | Q29547203 | ||
| mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt | Q29547767 | ||
| The STATs of cancer--new molecular targets come of age | Q29614601 | ||
| Ras, PI(3)K and mTOR signalling controls tumour cell growth | Q29614734 | ||
| Targeting the phosphoinositide 3-kinase pathway in cancer | Q29615809 | ||
| Identification of a novel inhibitor of mitogen-activated protein kinase kinase | Q29616448 | ||
| Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer | Q29618030 | ||
| Phase II study of S-1 in patients with advanced biliary tract cancer | Q36696249 | ||
| Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes | Q36759538 | ||
| Comprehensive review of JAK inhibitors in myeloproliferative neoplasms. | Q36776428 | ||
| Whole-exome tumor sequencing study in biliary cancer patients with a response to MEK inhibitors | Q36905641 | ||
| Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer | Q36972551 | ||
| AKT and ERK1/2 signaling in intrahepatic cholangiocarcinoma | Q37045823 | ||
| Cooperative activation of PI3K by Ras and Rho family small GTPases | Q37058907 | ||
| The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy | Q37192611 | ||
| Enhancing therapeutic efficacy by targeting non-oncogene addicted cells with combinations of signal transduction inhibitors and chemotherapy | Q37192616 | ||
| Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941 | Q37281824 | ||
| Nonpharmacologic strategies for managing common chemotherapy adverse effects: a systematic review | Q37316300 | ||
| Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia | Q37331742 | ||
| The frequency of KRAS and BRAF mutations in intrahepatic cholangiocarcinomas and their correlation with clinical outcome | Q37337144 | ||
| Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. | Q37350230 | ||
| Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed. | Q37384293 | ||
| Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth In vitro | Q37385294 | ||
| Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements | Q37505185 | ||
| Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer. | Q37596249 | ||
| Emerging MEK inhibitors. | Q37691441 | ||
| STAT-3 inhibitors: state of the art and new horizons for cancer treatment. | Q37875175 | ||
| The ERK Cascade: Distinct Functions within Various Subcellular Organelles | Q37903694 | ||
| PI3K and STAT3: a new alliance. | Q37986079 | ||
| Recent advances in cancer stem cell research for cholangiocarcinoma | Q38036147 | ||
| Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines | Q38045304 | ||
| The clinical development of MEK inhibitors | Q38212717 | ||
| IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. | Q38343244 | ||
| Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors | Q38406496 | ||
| Combination of gemcitabine and cetuximab in patients with advanced cholangiocarcinoma: a phase II study of the Belgian Group of Digestive Oncology | Q38445683 | ||
| Tumor Microenvironment Versus Cancer Stem Cells in Cholangiocarcinoma: Synergistic Effects? | Q38584340 | ||
| Dual Inhibition of MEK and PI3K/Akt Rescues Cancer Cachexia through both Tumor-Extrinsic and -Intrinsic Activities | Q38733117 | ||
| Cobimetinib and vemurafenib for the treatment of melanoma | Q38783292 | ||
| Suppression of prostate cancer progression by cancer cell stemness inhibitor napabucasin | Q38792113 | ||
| Cobimetinib | Q38971855 | ||
| Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy | Q39129195 | ||
| Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity | Q29618117 | ||
| Improved survival with MEK inhibition in BRAF-mutated melanoma | Q29620663 | ||
| Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. | Q30317428 | ||
| Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials | Q30318857 | ||
| Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer | Q33214444 | ||
| Signalling responses linked to betulinic acid-induced apoptosis are antagonized by MEK inhibitor U0126 in adherent or 3D spheroid melanoma irrespective of p53 status | Q33223047 | ||
| Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma. | Q33237214 | ||
| Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer | Q33336807 | ||
| Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma | Q33343774 | ||
| Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial | Q33359839 | ||
| Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma | Q33361810 | ||
| Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study | Q33362191 | ||
| Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial | Q33363800 | ||
| Single-agent gemcitabine in the treatment of advanced biliary tract cancers: a phase II study | Q33364964 | ||
| Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial | Q33365628 | ||
| Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma. | Q33369276 | ||
| Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer | Q33372640 | ||
| Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer | Q33375714 | ||
| Chemotherapy with gemcitabine and oxaliplatin in patients with advanced biliary tract cancer: a single-institution experience | Q33379677 | ||
| Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study | Q33383423 | ||
| Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study | Q33385766 | ||
| The cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG) regimen in advanced biliary tract adenocarcinoma | Q33388402 | ||
| Feasibility study of gemcitabine and cisplatin combination chemotherapy for patients with refractory biliary tract cancer. | Q33390549 | ||
| Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan | Q33390747 | ||
| Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis | Q33391880 | ||
| Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study. | Q33392786 | ||
| A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: a multicentre, multinational study | Q33398787 | ||
| Phase I trial of combination chemotherapy with gemcitabine, cisplatin, and S-1 in patients with advanced biliary tract cancer | Q33423185 | ||
| Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin | Q33503141 | ||
| In vitro and in vivo radiosensitization with AZD6244 (ARRY-142886), an inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinase | Q33557673 | ||
| STAT inhibitors for cancer therapy. | Q33644206 | ||
| Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas | Q33750719 | ||
| Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas | Q33914989 | ||
| Gemcitabine and cisplatin for inoperable and/or metastatic biliary tree carcinomas: a multicenter phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM). | Q33996606 | ||
| Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. | Q53393758 | ||
| Antiangiogenic effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor. | Q53423714 | ||
| Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma. | Q53576256 | ||
| Phase 1 and pharmacological trial of OPB-31121, a signal transducer and activator of transcription-3 inhibitor, in patients with advanced hepatocellular carcinoma. | Q53610627 | ||
| Variable apoptotic response of NSCLC cells to inhibition of the MEK/ERK pathway by small molecules or dominant negative mutants. | Q53961769 | ||
| Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors. | Q54454666 | ||
| First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors. | Q54499836 | ||
| A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy. | Q54588857 | ||
| Promoter hypermethylation of DAP-kinase is associated with poor survival in primary biliary tract carcinoma patients. | Q54698478 | ||
| Effects of valproic acid in combination with S-1 on advanced pancreatobiliary tract cancers: clinical study phases I/II | Q57150032 | ||
| Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer | Q57152489 | ||
| Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours | Q61868335 | ||
| 5-Fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract | Q72398245 | ||
| Epirubicin-sequential methotrexate-5-fluorouracil-leucovorin treatment in advanced cancer of the extrahepatic biliary system. A phase II study | Q72447982 | ||
| p53 overexpression and K-ras gene mutations in primary sclerosing cholangitis-associated biliary tract cancer | Q73445284 | ||
| Mutations of p53 tumor suppressor gene, apoptosis, and proliferation in intrahepatic cholangiocellular carcinoma of the liver | Q73534877 | ||
| Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients | Q73873388 | ||
| Phase II trial of docetaxel for cholangiocarcinoma | Q74455186 | ||
| A phase II trial of 5-fluorouracil, leucovorin, and carboplatin in patients with unresectable biliary tree carcinoma | Q74681551 | ||
| Weekly 24 h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract carcinomas | Q74770975 | ||
| Expression of G1-S modulators (p53, p16, p27, cyclin D1, Rb) and Smad4/Dpc4 in intrahepatic cholangiocarcinoma | Q78368579 | ||
| Frequent loss of chromosome 3p and hypermethylation of RASSF1A in cholangiocarcinoma | Q78424694 | ||
| Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis | Q78836958 | ||
| Rare PIK3CA hotspot mutations in carcinomas of the biliary tract | Q80462548 | ||
| Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer | Q80605580 | ||
| A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens | Q82758717 | ||
| STATs profiling reveals predominantly-activated STAT3 in cholangiocarcinoma genesis and progression | Q45011155 | ||
| Small cell lung cancer cells express EGFR and tyrosine phosphorylation of EGFR is inhibited by gefitinib ("Iressa", ZD1839). | Q45113621 | ||
| Randomised phase II trial of photodynamic therapy plus oral fluoropyrimidine, S-1, versus photodynamic therapy alone for unresectable hilar cholangiocarcinoma | Q45190482 | ||
| Aging-suppressants: cellular senescence (hyperactivation) and its pharmacologic deceleration. | Q46008332 | ||
| Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research | Q46453554 | ||
| Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies | Q46595207 | ||
| Detection of response-predicting mutations in the kinase domain of the epidermal growth factor receptor gene in cholangiocarcinomas | Q46609599 | ||
| The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel | Q46825496 | ||
| Phase II study of epirubicin, cisplatin, and capecitabine for advanced biliary tract adenocarcinoma | Q46846035 | ||
| Pegylated wortmannin and 17-hydroxywortmannin conjugates as phosphoinositide 3-kinase inhibitors active in human tumor xenograft models | Q46945964 | ||
| Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies | Q47576734 | ||
| Alterations of p16 and prognosis in biliary tract cancers from a population-based study in China | Q47969024 | ||
| Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme | Q48058166 | ||
| Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma | Q48568468 | ||
| Phase II trial of intravenous flourouracil and subcutaneous interferon alfa-2b for biliary tract cancer | Q50163824 | ||
| Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition | Q50335943 | ||
| A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies. | Q50483589 | ||
| Phase I trial of S-1 every other day in combination with gemcitabine/cisplatin for inoperable biliary tract cancer. | Q50609881 | ||
| A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors. | Q51636999 | ||
| Treatment of inoperable and/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study. | Q52935096 | ||
| Liver stem cells and their implication in hepatocellular and cholangiocarcinoma | Q33997118 | ||
| Phase II study of erlotinib in patients with advanced biliary cancer | Q33997258 | ||
| MEK and the inhibitors: from bench to bedside | Q34036341 | ||
| Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study | Q34048813 | ||
| Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. | Q34099883 | ||
| Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors | Q34104493 | ||
| A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer | Q34106382 | ||
| RAS Interaction with PI3K: More Than Just Another Effector Pathway | Q34202692 | ||
| Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials | Q34576456 | ||
| Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention | Q34595904 | ||
| Inactivation of RASSF1A, the tumor suppressor gene at 3p21.3 in extrahepatic cholangiocarcinoma | Q34605107 | ||
| Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer | Q34618537 | ||
| Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity | Q34627947 | ||
| Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma | Q34633455 | ||
| The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures | Q34674397 | ||
| Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers | Q35023456 | ||
| FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma | Q35078039 | ||
| Targeting the STAT3 signaling pathway in cancer: role of synthetic and natural inhibitors. | Q35081777 | ||
| Suppression of cancer relapse and metastasis by inhibiting cancer stemness | Q35090120 | ||
| Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. | Q35166852 | ||
| Comparison of single-agent chemotherapy and targeted therapy to first-line treatment in patients aged 80 years and older with advanced non-small-cell lung cancer | Q35535417 | ||
| Clinical development of phosphatidylinositol-3 kinase pathway inhibitors | Q35566234 | ||
| Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health | Q35679353 | ||
| Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer | Q35696749 | ||
| Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping | Q35705307 | ||
| Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells | Q35987390 | ||
| Wnt/β-Catenin Signaling in T-Cell Immunity and Cancer Immunotherapy | Q36085806 | ||
| Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer | Q36086845 | ||
| The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions | Q36360691 | ||
| Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing | Q36388792 | ||
| A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202. | Q36459140 | ||
| Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial | Q36614800 | ||
| Hepatic resection in the treatment of hilar cholangiocarcinoma | Q36680831 | ||
| Stat3 promotes metastatic progression of prostate cancer. | Q36691140 | ||
| Dual Inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors | Q39140529 | ||
| Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines | Q39362181 | ||
| Fully activated MEK1 exhibits compromised affinity for binding of allosteric inhibitors U0126 and PD0325901. | Q39500057 | ||
| Acquisition of chemoresistance in intrahepatic cholangiocarcinoma cells by activation of AKT and extracellular signal-regulated kinase (ERK)1/2. | Q39624022 | ||
| Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia. | Q39650704 | ||
| Quantifying pharmacologic suppression of cellular senescence: prevention of cellular hypertrophy versus preservation of proliferative potential | Q39739137 | ||
| Growth inhibition of human ovarian cancer cells by blocking STAT3 activation with small interfering RNA. | Q39780877 | ||
| E6201 [(3S,4R,5Z,8S,9S,11E)-14-(ethylamino)-8, 9,16-trihydroxy-3,4-dimethyl-3,4,9,19-tetrahydro-1H-2-benzoxacyclotetradecine-1,7(8H)-dione], a novel kinase inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (M | Q39812078 | ||
| A novel dual PI3Kalpha/mTOR inhibitor PI-103 with high antitumor activity in non-small cell lung cancer cells | Q39840228 | ||
| Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab | Q39840667 | ||
| Pharmacologic inhibition of MEK and PI-3K converges on the mTOR/S6 pathway to decelerate cellular senescence | Q39845659 | ||
| PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers | Q39859169 | ||
| p42/p44-MAPK and PI3K are sufficient for IL-6 family cytokines/gp130 to signal to hypertrophy and survival in cardiomyocytes in the absence of JAK/STAT activation. | Q39885290 | ||
| Endoscopic removal of a tablespoon lodged within the duodenum | Q39924490 | ||
| BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins | Q39954401 | ||
| Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity. | Q39960673 | ||
| AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in precl | Q40093939 | ||
| Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor | Q40164535 | ||
| The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells | Q40169305 | ||
| A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma | Q40280414 | ||
| Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor | Q40290597 | ||
| Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth | Q40394995 | ||
| PWT-458, a novel pegylated-17-hydroxywortmannin, inhibits phosphatidylinositol 3-kinase signaling and suppresses growth of solid tumors | Q40431830 | ||
| Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: A large multicenter study by the Association des Gastro-Entérologues Oncologues. | Q40860251 | ||
| Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity | Q40944056 | ||
| Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells | Q40972355 | ||
| Role of epidermal growth factor receptor and STAT-3 activation in autonomous proliferation of SUM-102PT human breast cancer cells | Q41125780 | ||
| Inhibition of the AKT pathway in cholangiocarcinoma by MK2206 reduces cellular viability via induction of apoptosis. | Q41854656 | ||
| Novel ATP-competitive MEK inhibitor E6201 is effective against vemurafenib-resistant melanoma harboring the MEK1-C121S mutation in a preclinical model | Q42241999 | ||
| A Phase II, Open-Label, Randomized Study to Assess the Efficacy and Safety of AZD6244 (ARRY-142886) Versus Pemetrexed in Patients with Non-small Cell Lung Cancer Who Have Failed One or Two Prior Chemotherapeutic Regimens | Q42673662 | ||
| Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors | Q42721039 | ||
| Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma | Q43005729 | ||
| Frequency of p16(INK4A) alterations and K-ras mutations in intrahepatic cholangiocarcinoma of the liver | Q43086184 | ||
| Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study | Q43237133 | ||
| Capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective single-center study | Q43589273 | ||
| A phase II trial of irinotecan (CPT-11) for unresectable biliary tree carcinoma. | Q43634488 | ||
| First-line chemotherapy with docetaxel for unresectable or metastatic carcinoma of the biliary tract. A multicentre phase II study | Q43750756 | ||
| Outpatient therapy with gemcitabine and docetaxel for gallbladder, biliary, and cholangio-carcinomas | Q44118434 | ||
| Roles of activated Src and Stat3 signaling in melanoma tumor cell growth | Q44172485 | ||
| Prospective evaluation of efficacy and toxicity of 5-fu and folinic acid (Mayo Clinic regimen) in patients with advanced cancer of the gallbladder | Q44417546 | ||
| Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805). | Q44488107 | ||
| Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer | Q44508387 | ||
| Clinical significances of cancer stem cells markers in patients with intrahepatic cholangiocarcinoma who underwent hepatectomy | Q44723058 | ||
| Comparison of 5-fluorouracil, doxorubicin and mitomycin C with 5-fluorouracil alone in the treatment of pancreatic-biliary carcinomas | Q44896529 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 485-498 | |
| P577 | publication date | 2017-03-17 | |
| P1433 | published in | Expert Opinion on Therapeutic Targets | Q5421214 |
| P1476 | title | Signaling pathways as therapeutic targets in biliary tract cancer | |
| P478 | volume | 21 |
| Q64249982 | Targeted Therapies in Cholangiocarcinoma: Emerging Evidence from Clinical Trials | cites work | P2860 |
Search more.